恩瑞格上市了吗？

Is it on the market? Deferasirox (Enriga) is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

Deferasirox dispersible tablets are a new type of oral iron-removing agent, used for patients with iron accumulation due to long-term blood transfusion (such as those suffering from thalassemia or other rare anemias). It is suitable for children over two years old and adults. Clinical research is currently underway in China. Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, can significantly reduce the iron load on the heart and liver, and is easily accepted by patients. Deferasirox is currently sold in China under the brand name Enrig. Deferasirox is a new type of active iron chelator that is highly selective with iron (Fe3+). It is mainly suitable for the treatment of chronic iron overload caused by frequent blood transfusions (monthly dosage of concentrated red blood cells ≥7mL/kg) in patients with β-thalassemia over 6 years old.

Deferasirox is a ligand with three protrusions. Although its affinity for zinc and copper is very low, the concentrations of these trace metals in the serum decreased to varying degrees after administration. The tolerability and safety of deferasirox are relatively good among similar drugs. Therefore, patients can also take it for a long time, but it is best to consult a doctor first and use it under the guidance of a doctor to avoid adverse reactions.